FISCHER MEDICAL VENTURES LIMITED
Registered Office Address: Survey No. 480/2 AP Medtech Zone
Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032
CIN: L86900AP1993PLC118162
Email: enquiry@fischermv.com | Website: www.fischermv.com | Contact 9080966548

July 30, 2026

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd.
Exchange Plaza, 5tll floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051
NSE Symbol: FISCHER

Dear Sir,

Reg : Press Release on Fischer Medical Ventures Secures CDSCO Import Approval for Spincare — India's First Regulatory Clearance for a Portable Electrospun Wound Care System

---

We enclose a press release regarding **Fischer Medical Ventures Secures CDSCO Import Approval for Spincare — India's First Regulatory Clearance for a Portable Electrospun Wound Care System**, for dissemination.

Thanking you,

Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

BALAJI GANDLA
Digitally signed by BALAJI GANDLA
Date: 2026.07.30 15:04:28 +05'30'

Fischer Medical Ventures Limited

BALAJI GANDLA

COMPANY SECRETARY & COMPLIANCE OFFICER

CIN L86900AP1993PLC118162

Corporate Office	**:**	**Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006.**
Registered Office	**:**	**No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032.**

Fischer Medical Ventures Secures CDSCO Import Approval for Spincare — India's First Regulatory Clearance for a Portable Electrospun Wound Care System

Permission No. IMP/MD/2026/000455 | Class C Medical Device

Chennai, India: July 30, 2026 — Fischer Medical Ventures announced today that Nanomedic Technologies Ltd. (Lod, Israel), its associate company, has received regulatory clearance from India's Central Licensing Authority (CDSCO) to import and distribute the Spincare Portable Wound Care System. The approval, issued under Form MD-27 of the Medical Devices Rules, 2017, marks a significant regulatory milestone and positions Fischer Medical Ventures at the forefront of India's rapidly growing advanced wound care market.

A First-of-Its-Kind Device Enters the Indian Market
The Spincare system is a portable, hand-held device that applies a breathable, transparent nano-fiber film directly onto wounds at the point of care — eliminating the need for traditional dressings in many clinical scenarios. Cleared as a **Class C medical device**, Spincare is indicated for use across a broad range of skin breaches including:

- Partial and full thickness wounds
- Superficial and partial thickness burns
- Donor site wounds
- Surgical incisions and post-suture sites
- Skin tears, dermatological lesions, and chronic ulcers

The system is designed for use by healthcare professionals in clinical environments and carries a five-year shelf life.

Please find below a link for the live demonstration of the Spincare Product: https://www.youtube.com/watch?v=liJq_4V_mH0

Market Opportunity

India represents a significant and rapidly expanding wound care market, currently valued at approximately **USD 380 million in 2026** and projected to reach **USD 1.8 billion by 2033**, growing at a CAGR of ~6.4% *(Source: IMARC Group, India Wound Care Market Report, 2026)*. Rising diabetes prevalence, increasing surgical volumes, and the growth of home healthcare are key demand drivers.

Southeast Asia presents equally compelling growth. The region's advanced wound care segment is projected to reach **USD 354 million by 2030** (CAGR ~6.1%) *(Source: Grand View Research, South East Asia Advanced Wound Care Market Report, 2030)*. Countries such as Indonesia, Malaysia, and Singapore are witnessing accelerating demand driven by increasing awareness of wound management and a rising burden of chronic diseases.

Exclusive Distribution Partnership

As Nanomedic Technologies Ltd.'s dedicated business partner, Fischer Medical Ventures holds the **exclusive rights to distribute the Spincare system across India and Southeast Asia**. With India's wound care market valued at approximately USD 380 million in 2026 (projected to reach USD 1.8 billion by 2033; Source: IMARC Group) and Southeast Asia's advanced wound care segment on track to reach USD 354 million by 2030 (Source: Grand View Research), Fischer is strategically positioned to capture a significant share of this combined multi-billion dollar opportunity. This partnership enables Fischer to bring a globally proven, first-of-its-kind wound care technology to some of the world's fastest-growing healthcare markets.

FDA Approval in Progress

Nanomedic Technologies Ltd., Fischer's associate company, has submitted its application for **U.S. Food and Drug Administration (FDA) approval** for Spincare. The approval process is currently underway, and Nanomedic Technologies Ltd. expects to receive FDA clearance soon. This milestone will further validate the product's safety and efficacy standards and strengthen the group's standing in global markets.

Management Commentary

"Receiving CDSCO clearance for Spincare is a transformative moment for Fischer Medical Ventures. This approval opens the door to deploying a genuinely differentiated wound care technology across Indian hospitals and burn centers. We see substantial whitespace in this market and are moving quickly to establish our commercial footprint." — **Mr. Ravindran Govindan, Chairman & Managing Director, Fischer Medical Ventures Limited.**

About the Spincare System

The Spincare Portable Wound Care System is manufactured by **Nanomedic Technologies Ltd.**, headquartered in Lod, Israel. The system leverages proprietary electrospinning technology to create a nano-fiber protective layer on wounds in real time, accelerating healing and reducing infection risk. It has received regulatory approvals in multiple jurisdictions globally.

About Fischer Medical Ventures

Fischer Medical Ventures Limited (FMV) is driving a global shift in healthcare through innovative, cost-effective medical imaging and advanced diagnostics. Beyond medical devices, FMV offers a wide range of point-of-care diagnostic solutions, enabling timely and accurate patient care. Leveraging expertise, resources, and strategic partnerships, the company is committed to enhancing accessibility, affordability, and progress in healthcare delivery, creating a meaningful impact on healthcare systems worldwide.

For further information, please contact:
Fischer Medical Ventures Limited
Email: **enquiry@fischermv.com**
Website: **www.fischermv.com**
Contact: **9080966548**

Disclaimer:

This investor release is not an offer to sell any securities or a solicitation to buy any securities of Fischer Medical Ventures Limited (the "company") or its subsidiaries (together with the company, the "group"). Certain statements in this document may be forward looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", " estimates"," anticipates", " projects", " expects", " intends", " may", " will"," or " or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intention. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Investor Release, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. **FISCHERMVL** will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward- looking statements to reflect subsequent events or circumstances.

***